Edelweiss Board Meeting to Consider Q3 Unaudited Financial Results

Edelweiss has announced a board meeting scheduled for February 10, 2026, to consider the unaudited financial results for the third quarter (Q3: Oct-Dec) and the nine-month period ending December 31, 2025. The board will review both standalone and consolidated figures. An official announcement with detailed financial results will follow the meeting.

Board to Review Q3 Results

The Board of Directors of Edelweiss will convene on February 10, 2026, to review and approve the company’s unaudited financial performance for the third quarter of fiscal year 2026 (Q3: Oct-Dec). The results will cover the period ending December 31, 2025.

Standalone and Consolidated Figures

The board will consider both standalone and consolidated unaudited financial results. Following the meeting, the company will release an official statement detailing its financial performance and key highlights for the quarter. Investors and stakeholders can anticipate further details after the board’s deliberation.

Source: BSE

Previous Article

Aarti Drugs Board Approves Interim Dividend for FY 2025-26

Next Article

Aarti Drugs Interim Dividend Declared for Financial Year 2025-26